drugset / Trial / NCT03611569

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569 ↗

Phase 1 Completed 74 enrolled H. Lundbeck A/S
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease

Timeline

Start
2018-07-25
Primary completion
2021-07-26
Completion
2021-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlenetug Monoclonal antibody — —

Indications